MT1002 clinical trials
How each study uses MT1002 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MT1002 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MT1002 for Injection
- 3
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Shaanxi Micot Technology Limited Company (3) · Shaanxi Micot Pharmaceutical Technology Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses MT1002 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCIRecruitingPhase 2Shaanxi Micot Technology Limited CompanyNCT06533358Written as MT1002 InjectionHow we know
- MT1002 Phase II Study in ACS Patients With PCITerminatedPhase 2Shaanxi Micot Pharmaceutical Technology Co., Ltd.NCT04723186Written as MT1002 for InjectionHow we know
- Evaluate the Effects of Renal Impairment on the Pharmacokinetics and PharmacodynamicsTerminatedPhase 1Shaanxi Micot Technology Limited CompanyNCT05323136Written as MT1002 for InjectionHow we know
- Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for InjectionCompletedPhase 1Shaanxi Micot Technology Limited CompanyNCT04116840Written as MT1002 for injectionHow we know